Amarin Corp Plc (AMRN)

[ziploc_1]

After being invested in Amarin for close to 15 years, my current conclusions are that...the main upside for Amarin now depends on catalysts such as...
-reimbursement for Vascepa in mainland China
-reimbursement for Vascepa in major European countries
-court decisions discouraging further infringement on Vascepa CVD patents by generics
-a patented new EPA product being introduced into U.S. market
-new evidence of effectiveness of Vascepa in other diseases in addition to CVD...such as in Alzheimers or cancers

Waiting for these catalysts to materialize, it would be well for Amarin to preserve its cash, in order to withstand any negative catalysts that might arise....and, if the opportunity arises, to spend the cash on something that might increase its revenues


for those reasons, I am not eager for Amarin to spend $50 million on the buy back of its stock.

One of the good things about Amarin's current situation is that it has plenty of cash and no debt.